Aurinia (Canada)

Recent papers from Aurinia (Canada)

1. In Vitro Enteral Feeding Tube Study for Lacosamide Extended-release Capsules (P3-10.010)Neurology · 2026
2. Voclosporin ameliorates proteinuria in a model of non-inflammatory glomerular diseaseBMC Nephrology · 2026
3. Investigation of Renal Tissue Deposition of the Calcineurin Inhibitors Voclosporin, Cyclosporine and Tacrolimus Using MALDI-MSI ImagingPharmaceutical Research · 2026
4. Achievement of Proteinuria Less Than 0.4 G/G in the Phase 3 Aurora 1 Study of Voclosporin in Lupus NephritisThe Journal of Rheumatology · 2025
5. Effect of Long‐Term Voclosporin Treatment on Renal Histology in Patients With Active Lupus Nephritis With Repeat Renal BiopsiesArthritis & Rheumatology · 2025
6. The kidney injury biomarker profile of patients with lupus nephritis remains unchanged with the second-generation calcineurin inhibitor voclosporinFrontiers in Nephrology · 2025
7. Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple MyelomaClinical Cancer Research · 2025
8. Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMSLupus Science & Medicine · 2024
9. Efficacy and safety of a diffusion-based extended-release fluticasone propionate intra-articular injection (EP-104IAR) in knee osteoarthritis (SPRINGBOARD): a 24-week, multicentre, randomised, double-blind, vehicle-controlled, phase 2 trialThe Lancet Rheumatology · 2024
10. Initial Results From Resolve, a Phase 1b Dose-Escalation Study of Ep-104gi (Extended-Release Fluticasone Propionate Intra-Esophageal Injection) for Eosinophilic EsophagitisDiseases of the Esophagus · 2024
11. Evaluating the cost-effectiveness of voclosporin for the treatment of lupus nephritis in the United StatesJournal of Managed Care & Specialty Pharmacy · 2024
12. Pharmacokinetics and Safety of a 1:1 Mixture of Doxecitine and Doxribtimine: Open-label Phase 1 Single Ascending Dose and Food Effect Studies in Healthy AdultsClinical Therapeutics · 2024
13. Op0247 Efficacy of a Novel Long-Acting Fluticasone Propionate Intra Articular Injection (Ep-104iar) in Knee Osteoarthritis: Per-Protocol Analysis of a Randomised, Double-Blind, Phase 2 Trial of Ep-104iar vs Vehicle Placebo (Springboard)Annals of the Rheumatic Diseases · 2024
14. Calcineurin inhibitor effects on kidney electrolyte handling and blood pressure: tacrolimus versus voclosporinNephrology Dialysis Transplantation · 2024
15. Effects of Second-Generation Calcineurin Inhibitor, Voclosporin, on Calcineurin Isoform Activity and Nephrotoxicity in Comparison to Cyclosporine and TacrolimusJournal of Pharmacology and Experimental Therapeutics · 2024
16. Voclosporin Induces Systemic Lipidomic Alterations: Implications for Lupus Nephritis RemissionKidney International Reports · 2024
17. #468 Voclosporin-based, triple-immunosuppressive therapy vs high-dose glucocorticoid-based dual-immunotherapy for lupus nephritis: a propensity analysisNephrology Dialysis Transplantation · 2024
18. 1007 Voclosporin for lupus nephritis: assessment of long-term safety and efficacy including renal outcome over three years of treatment in the phase 3 AURORA 1 and AURORA 2 studiesBMJ · 2024
19. P87 Comparison of a voclosporin-based, triple immunotherapy regimen to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV plus AURORA 1 studies and ALMSPoster presentations · 2024
20. Efficacy of Voclosporin in Proliferative Lupus Nephritis with High Levels of ProteinuriaClinical Journal of the American Society of Nephrology · 2023